GSK Investigational Site

Charleroi 6060

1 studies enrolling now · 10 studies all time

What they study most

HIV Infection, HIV Infections, Infection, Human Immunodeficiency Virus, Lung Cancer, Non-Small Cell, Melanoma, Neoplasms, Breast, Neoplasms, Head and Neck, Restless Legs Syndrome, Restless Legs Syndrome (RLS), Thrombocytopaenia

Studies at this site

• A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma — Recruiting now
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease — Running, not enrolling
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults — Completed
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma — Completed
• A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer — Completed
• RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole — Completed
• Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag — Completed
• KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks — Completed
• Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 — Stopped early